Article: Correction.(to 'Clobetasol Propionate Foam Reduced Scalp Psoriasis', May 1, 2000 issue)(Correction Notice)

Article: Treatment of Hailey-Hailey disease with tacrolimus ointment and ...
Journal of Drugs in Dermatology;  March 1, 2004 ;     700+ words ... ... day for six week periods alternating with the clobetasol propionate foam for six week periods. During the latter cycle, clobetasol propionate foam was applied as little as two times per week ...

Article: Clobetasol Propionate Foam Reduced Scalp ...
Family Practice News;  May 1, 2000 ;     535 words ... ... that 74% of patients on clobetasol propionate foam improved 50% or more ... of patients receiving clobetasol propionate solution. Improvement ... Administration approval of clobetasol propionate foam is expected by late summer ...

Article: Stiefel Laboratories Receives FDA Approval of Olux-E ...
Business Wire;  January 23, 2007 ;     700+ words ... ... approved Olux-E[TM] (clobetasol propionate) Foam, 0.05%. Olux ... include: Olux([R]) (clobetasol propionate) Foam, 0.05%; Luxiq ... are Olux-E[TM] (clobetasol propionate) Foam, 0.05%, and Verdeso ...

Article: Perrigo Company Announces Launch of Clobetasol ...
PR Newswire;  March 20, 2008 ;     700+ words ... ... preliminary injunction related to Perrigo's Clobetasol Propionate Foam, the AB-rated generic equivalent to Connetics ... healthcare more affordable for our customers." Clobetasol Propionate Foam is a topical corticosteroid indicated for the ...

Article: Perrigo Company Receives Final Approval on Clobetasol ...
PR Newswire;  March 11, 2008 ;     700+ words ... ... from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Foam, 0.05%. The product is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis ...

Article: Stiefel Laboratories received FDA approval for Olux-E ...
Medical Marketing & Media;  March 1, 2007 ;     487 words ...Stiefel Laboratories received FDA approval for Olux-E (clobetasol propionate) foam, for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years ...

Article: Perrigo Receives Tentative Approval For Clobetasol ...
PR Newswire;  September 1, 2006 ;     700+ words ... ... approval from the U. S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Topical Foam, 0.05%. The reference listed drug (Olux(R) Foam, 0.05%, Connetics Corporation) is ...